 |
|
|
|
|
08.00 – 19.30 |
Registration open |
|
|
08.00 – 09.00 |
Posters |
|
Hall Agora 2 |
| |
|
|
|
|
09.00 – 10.00
|
Symposium 3
Bone Resorption Chair: P. Jurdic (Lyon, France),
A. Teti (L’Aquila, Italy)
|
|
Athena Theatre
|
| I012 |
|
Chloride channels and proton transport: CLC-7 regulates
bone density |
|
U. Kornak (Berlin, Germany)
|
| I013 |
|
Bone lining cells and the regulation of bone resorption |
|
V. Everts (Amsterdam, Netherlands) |
| |
|
|
|
|
10.00 – 11.00
|
Oral Presentations 4
Osteoclasts and Bone Resorption Chair: P. Jurdic (Lyon, France),
A. Teti (L’Aquila, Italy)
|
|
Athena Theatre
|
| OP016 |
|
Cannabinoid receptor antagonists inhibit osteoclastic
bone resorption in vitro and prevent ovariectomy induced bone loss
in vivo
ECTS Young Investigator Award |
|
A. Idris (Aberdeen, UK)
|
| OP017 |
|
Role of inositol polyphosphate 4-phosphatase type II
in osteoclast cytoskeletal organization and activity
ECTS Young Investigator Award |
|
M. Ferron (Montreal, Canada)
|
| OP018 |
|
Osteoclast alphaVbeta3 integrin-induced ERK1/2 activation
is intracellular Ca2+/c-Src-dependent, Shc/Ras/Raf-1-independent, and
is triggered by engagement of PKCalpha
ECTS Young Investigator Award |
|
N. Rucci (L'Aquila, Italy)
|
| OP019 |
|
Transdifferentiation of human dendritic cells towards
osteoclasts |
|
M. Mazzorana (Lyon, France)
|
| OP020 |
|
ABD56 a potent inhibitor of bone resorption, induces
osteoclast apoptosis via NFkB and ERK inhibition in vitro |
|
A. Idris (Aberdeen, UK)
|
| |
|
|
|
|
11.00 – 12.00 |
ECTS Annual General Meeting |
|
Athena Theatre |
11.00 – 12.45 |
Coffee and Posters |
|
Hall Agora 2 |
12.00 – 12.45 |
Lunch |
|
|
| |
|
|
|
|
12.45 – 14.00
|
Workshop 3
Tissue Engineering Chair: B.
Rossi (Nice, France),
E. Wagner (Vienna, Austria)
|
|
Hermès Theatre
|
| I014 |
|
Tissue engineering of cartilaginous tissues: gene enhancement
of chondrogenic cells |
|
T. E. Hardingham (Manchester, UK) |
| I015 |
|
Pluripotency of adult stem cells: instructions for osteogenic
lineage direction |
|
J. B. Lian (Worcester, USA) |
| I016 |
|
Engineering new bone with BMP's |
|
J. M. Wozney (Cambridge, USA) |
| |
|
|
|
|
12.45 – 14.00
|
Workshop 4
Rare Bone Diseases Chair: M.-C.
de Vernejoul (Paris, France),
W. van Hul (Antwerpen, Belgium)
|
|
Athena Theatre
|
| I017 |
|
Medical treatment of fibrous Dysplasia of bone |
|
P. Meunier (Lyon, France) |
| I018 |
|
Osteogenesis imperfecta & juvenile osteoporosis |
|
F. Glorieux (Montreal, Canada) |
| I019 |
|
Juvenile Paget's disease |
|
T. Cundy (Auckland, New Zealand) |
| |
|
|
|
|
14.00 – 15.00
|
Symposium 4
Metabolic Bone Diseases Chair: B.-L.
Langdahl (Aarhus, Denmark),
U. Kornak (Berlin, Germany)
|
|
Athena Theatre
|
| I020 |
|
Molecular mechanisms of phosphate transport in kidney
and bone: recent advances |
|
H. Tenenhouse (Montreal, Canada) |
| I021 |
|
Pathogenesis and treatment of osteoporosis in men |
|
J.-M. Kaufman (Ghent, Belgium) |
| |
|
|
|
|
15.00 – 16.00
|
Oral Presentations 5
Metabolic Bone Diseases Chair: B.-L.
Langdahl (Aarhus, Denmark),
U. Kornak (Berlin, Germany)
|
|
Athena Theatre
|
| OP021 |
|
RAS signaling regulates osteoblast differentiation and
extracellular matrix mineralization. Implications for the bone manifestations
of neurofibromatosis type I |
|
F. Elefteriou (Houston, USA)
|
| OP022 |
|
FGFR2 downregulation results from C-CBL-dependent FGFR2
proteasome degradation and contributes to increased osteoblast differentiation
in apert syndrome
ECTS Young Investigator Award
|
|
K. Kaabeche (Paris, France)
|
| OP023 |
|
Sequestosome 1 gene mutations lead to disregulated NFkB
signaling in Paget’s disease of bone |
|
A. Daroszewska (Aberdeen, UK)
|
| OP024 |
|
Twist haploinsufficiency in the Saethre-Chotzen syndrome
regulates osteoblast gene expression independently of FGFR2 signaling
ECTS Young Investigator Award |
|
H. Guénou (Paris, France)
|
| OP025 |
|
Alterations in transcriptional activity of the 24-Hydroxylase
gene due to a novel promoter polymorphism |
|
N. Schuetze (Wuerzburg, Germany) |
| |
|
|
|
|
16.00 – 16.30 |
Coffee Break |
|
|
| |
|
|
|
|
16.30 – 17.30
|
Oral Presentations 6
Management of Osteoporosis Chair: P.
Meunier (Lyon, France),
R. Eastell (Sheffield, UK)
|
|
Athena Theatre
|
| OP026 |
|
Head-to-head comparison of Risedronate and Alendronate |
|
C. Christiansen (Ballerup, Denmark) |
| OP027 |
|
Sustained effect of Risedronate on trabecular architecture
and mineralization over 5 years of treatment: triple biopsy studies
by micro-CT |
|
B. Borah (Mason, USA)
|
| OP028 |
|
Teriparatide (rhPTH [1-34]) treatment improves the structure
of the proximal femur in women with osteoporosis: results from the
fracture prevention trial |
|
E. F. Eriksen (Indianapolis, USA) |
| OP029 |
|
Strontium ranelate reduces the risk of vertebral and
non-vertebral fractures in caucasian women with post-menopausal osteoporosis |
|
S. Adami (Valeggio sul Mincio, Italy) |
| OP030 |
|
Effects of 10 years of estradiol on fracture risk and
other outcomes in early postmenopausal women - the Danish osteoporosis
prevention study |
|
L. Mosekilde (Aarhus, Denmark) |
| |
|
|
|
|
17.30 – 19.30
|
Satellite Symposium
Calcium and Vitamin D in Osteoporosis
Management
Supported by Nycomed Chair: P. Meunier (Lyon, France),
J.-Y. Reginster (Liège, Belgium)
|
|
Hermès Theatre
|
| S001 |
|
Osteoporosis: underestimated, under diagnosed, and
under treated |
|
S. Boonen (Leuven, Belgium) |
| S002 |
|
The effect of calcium and Vitamin D supplementation
on secondary hyperparathyroidism and bone resorption |
|
P. Lips (Amsterdam, Netherlands) |
| S003 |
|
Effect of Vitamin D and calcium in improving muscle
strength and reducing the risk of falls in older persons: a systematic
review |
|
H. A. Bischoff-Ferrari (Boston, USA) |
| S004 |
|
Efficacy of calcium and Vitamin D in reducing fracture
risk |
|
C. Cooper (Southampton, UK) |
| S005 |
|
The importance of compliance within osteoporosis in
general and with calcium and Vitamin D in particular |
|
Ö. Ljunggren (Uppsala, Sweden) |
| |
|
|
|
|
20.00 |
ECTS Football Cup |
|
Stade St Roch |
